ME01087B - Tretman limfoma t-ćelija primjenom 10-propargil-10-deazaaminopterina - Google Patents
Tretman limfoma t-ćelija primjenom 10-propargil-10-deazaaminopterinaInfo
- Publication number
- ME01087B ME01087B MEP-2008-310A MEP31008A ME01087B ME 01087 B ME01087 B ME 01087B ME P31008 A MEP31008 A ME P31008A ME 01087 B ME01087 B ME 01087B
- Authority
- ME
- Montenegro
- Prior art keywords
- cell lymphoma
- deazaaminopterin
- propargyl
- treatment
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52159304P | 2004-05-30 | 2004-05-30 | |
PCT/US2005/019169 WO2005117891A1 (en) | 2004-05-30 | 2005-05-31 | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
EP05756183A EP1750716B1 (en) | 2004-05-30 | 2005-05-31 | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
Publications (1)
Publication Number | Publication Date |
---|---|
ME01087B true ME01087B (me) | 2012-12-20 |
Family
ID=34971703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2008-310A ME01087B (me) | 2004-05-30 | 2005-05-31 | Tretman limfoma t-ćelija primjenom 10-propargil-10-deazaaminopterina |
Country Status (24)
Country | Link |
---|---|
US (4) | US7622470B2 (me) |
EP (1) | EP1750716B1 (me) |
JP (1) | JP5005532B2 (me) |
KR (1) | KR101189693B1 (me) |
CN (2) | CN102824346B (me) |
AT (1) | ATE405272T1 (me) |
AU (1) | AU2005249516B2 (me) |
BR (1) | BRPI0510895A (me) |
CA (1) | CA2565968C (me) |
DE (1) | DE602005009176D1 (me) |
DK (1) | DK1750716T3 (me) |
ES (1) | ES2313365T3 (me) |
HK (1) | HK1177901A1 (me) |
HR (1) | HRP20080569T3 (me) |
ME (1) | ME01087B (me) |
MX (1) | MXPA06013559A (me) |
NO (1) | NO337276B1 (me) |
NZ (2) | NZ551082A (me) |
PL (1) | PL1750716T3 (me) |
PT (1) | PT1750716E (me) |
RS (1) | RS50622B (me) |
SI (1) | SI1750716T1 (me) |
WO (2) | WO2005117891A1 (me) |
ZA (1) | ZA200609266B (me) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
WO2005117891A1 (en) | 2004-05-30 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
US8263354B2 (en) | 2004-05-30 | 2012-09-11 | Sloan-Kettering Institute For Cancer Research | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin |
US20080188479A1 (en) | 2004-05-30 | 2008-08-07 | Sloan-Kettering Institute For Cancer Research | Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin |
PT2650380E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
US20100248249A1 (en) * | 2007-08-17 | 2010-09-30 | Allos Therapeutics, Inc. | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels |
WO2009026234A1 (en) * | 2007-08-17 | 2009-02-26 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
US9901578B2 (en) | 2007-08-17 | 2018-02-27 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
CA2729622C (en) | 2008-07-03 | 2017-07-25 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
WO2010022277A2 (en) * | 2008-08-20 | 2010-02-25 | O'connor Owen A | Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
CN102753175A (zh) * | 2010-02-02 | 2012-10-24 | 艾洛斯治疗学有限公司 | 10-炔丙基-10-去氮杂氨基蝶呤之光学纯非对映体以及使用所述非对映体的方法 |
DK2575466T3 (en) * | 2010-06-02 | 2015-07-20 | Allos Therapeutics Inc | Methods of treating methotrexate resistant disorders of 10-propargyl-10-deazaaminopterin |
RU2013102373A (ru) * | 2010-08-10 | 2014-09-20 | Аллос Терапьютикс, Инк. | Продления выживаемости без прогрессирования заболевания с применением 10-пропаргил-10-деазааминоптерина |
WO2013164856A1 (en) | 2012-05-04 | 2013-11-07 | Avra Laboratories Private Limited | A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof |
CN103274943B (zh) * | 2013-05-24 | 2015-01-21 | 苏州明锐医药科技有限公司 | 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法 |
US11439643B2 (en) | 2015-06-16 | 2022-09-13 | Acrotech Biopharma Inc. | Combination therapy using belinostat and pralatrexate to treat lymphoma |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4393064A (en) | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
US4652533A (en) | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
DE69133095T2 (de) | 1990-11-20 | 2003-03-27 | Dade Behring Marburg Gmbh | Cyclosporin-Immunoassay |
US5354751A (en) | 1992-03-03 | 1994-10-11 | Sri International | Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis |
US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
US6028071A (en) * | 1996-07-17 | 2000-02-22 | Sloan-Kettering Institute For Cancer Research | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
US6323205B1 (en) | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
GB0128510D0 (en) * | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
WO2005117891A1 (en) * | 2004-05-30 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
-
2005
- 2005-05-31 WO PCT/US2005/019169 patent/WO2005117891A1/en active Application Filing
- 2005-05-31 CA CA2565968A patent/CA2565968C/en active Active
- 2005-05-31 AT AT05756183T patent/ATE405272T1/de active
- 2005-05-31 NZ NZ551082A patent/NZ551082A/en unknown
- 2005-05-31 RS RSP-2008/0470A patent/RS50622B/sr unknown
- 2005-05-31 PT PT05756183T patent/PT1750716E/pt unknown
- 2005-05-31 US US11/141,868 patent/US7622470B2/en active Active
- 2005-05-31 AU AU2005249516A patent/AU2005249516B2/en active Active
- 2005-05-31 ME MEP-2008-310A patent/ME01087B/me unknown
- 2005-05-31 WO PCT/US2005/019170 patent/WO2005117892A1/en active Application Filing
- 2005-05-31 CN CN201210342831.8A patent/CN102824346B/zh active Active
- 2005-05-31 US US11/568,254 patent/US7939530B2/en active Active
- 2005-05-31 PL PL05756183T patent/PL1750716T3/pl unknown
- 2005-05-31 KR KR1020117012373A patent/KR101189693B1/ko active IP Right Grant
- 2005-05-31 NZ NZ576849A patent/NZ576849A/en unknown
- 2005-05-31 ES ES05756183T patent/ES2313365T3/es active Active
- 2005-05-31 MX MXPA06013559A patent/MXPA06013559A/es active IP Right Grant
- 2005-05-31 EP EP05756183A patent/EP1750716B1/en active Active
- 2005-05-31 CN CNA2005800173160A patent/CN1960734A/zh active Pending
- 2005-05-31 DE DE602005009176T patent/DE602005009176D1/de active Active
- 2005-05-31 DK DK05756183T patent/DK1750716T3/da active
- 2005-05-31 SI SI200530392T patent/SI1750716T1/sl unknown
- 2005-05-31 BR BRPI0510895-0A patent/BRPI0510895A/pt not_active Application Discontinuation
- 2005-05-31 JP JP2007515512A patent/JP5005532B2/ja active Active
- 2005-05-31 ZA ZA200609266A patent/ZA200609266B/xx unknown
-
2006
- 2006-12-22 NO NO20065971A patent/NO337276B1/no unknown
-
2008
- 2008-11-11 HR HR20080569T patent/HRP20080569T3/xx unknown
-
2009
- 2009-10-21 US US12/603,117 patent/US8299078B2/en active Active
-
2012
- 2012-10-29 US US13/663,234 patent/US20130053391A1/en not_active Abandoned
-
2013
- 2013-05-13 HK HK13105681.8A patent/HK1177901A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1177901A1 (en) | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t | |
IL145487A0 (en) | Apomorphine and sildenafil composition | |
WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
JP2002523370A5 (me) | ||
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
MXPA05012810A (es) | Formas de dosis oral de memantina. | |
NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
SI1485051T1 (sl) | Postopek dajanja buprenorfina za zdravljenje depresije | |
RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
PL1689404T3 (pl) | Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka | |
NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
RU2005114664A (ru) | Способ лечения хронического панкреатита | |
WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
TW200626172A (en) | Treatment of HIV infection | |
WO2007093519A3 (en) | Ibandronate regimen for treating metastatic bone pain | |
RU2002128958A (ru) | Способ лечения онкологических больных | |
UA3797U (uk) | Спосіб лікування тяжких проникаючих поранень ока |